Arrowhead says FDA grants plozasiran entry into STAR pilot program for severe hypertriglyceridemia sNDA

PUBT · 2d ago
Arrowhead says FDA grants plozasiran entry into STAR pilot program for severe hypertriglyceridemia sNDA
  • FDA granted plozasiran entry into the STAR pilot program for an sNDA in severe hypertriglyceridemia.
  • STAR acceptance positions the filing for a 6-month Priority Review, with a potential action at least one month earlier.
  • Arrowhead targets year-end 2026 for the sNDA submission, keeping its Priority Review Voucher for another use or monetization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070730BIZWIRE_USPR_____20261007_BW808152) on October 07, 2026, and is solely responsible for the information contained therein.